Compound 2 (5.4 g, 9.72 mmol), H-Lys(Boc)-OMeHCl (3.46 g, 11.52 mmol), HATU (7.42 g, 19.44 mmol) and HOAT (2.64 g, 19.44 mmol) were dissolved in DMF (80 mL) under nitrogen atmosphere and ice bath conditions
Total weight loss at 48-68 weeks on the combination is difficult to predict without clinical trial data, but based on individual compound data (retatrutide at 24-28.7% and the additive benefit seen with CagriSema), a reasonable estimate for the combination is 25-35% total body weight reduction in high responders
In the case of Wegovy, additional adverse events reported after it was released to market include: Gastrointestinal disorders, including acute pancreatitis, necrotizing pancreatitis (when part of the pancreas dies) that sometimes results in death, and ileus when muscles in the intestine stop working and food and waste cant pass through the body normally
Hyperemesis gravidarum: This pregnancy complication is characterized by severe nausea and vomiting
Targeting GLP-1 signaling ameliorates cystogenesis in a zebrafish model of nephronophthisis